NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Recurrent Adult Soft Tissue Sarcoma
Stage III Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma

Interventions: Drug: perifosine
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-07-09

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00064324

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: gemcitabine hydrochloride
Radiation: radiation therapy
Other: laboratory biomarker analysis

First Posted Date: 2003-07-09

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT00063947

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer

Phase 1

Terminated

Conditions: Adenocarcinoma of the Esophagus
Mixed Adenocarcinoma of the Stomach
Recurrent Esophageal Cancer
Stage IIIA Gastric Cancer
Stage IV Esophageal Cancer
Adenocarcinoma of the Gastroesophageal Junction
Diffuse Adenocarcinoma of the Stomach
Recurrent Gastric Cancer
Squamous Cell Carcinoma of the Esophagus
Stage III Esophageal Cancer

Interventions: Biological: oblimersen sodium
Drug: cisplatin
Drug: fluorouracil

First Posted Date: 2003-07-09

Last Posted Date: 2021-02-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00064259

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer

Phase 1

Completed

Conditions: Recurrent Prostate Carcinoma
Stage IV Prostate Cancer AJCC v7

Interventions: Biological: Ipilimumab
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Biological: Sargramostim

First Posted Date: 2003-07-09

Last Posted Date: 2020-07-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT00064129

Locations: 🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States

Type 2 Diabetes Primary Prevention for At Risk Girls

Phase 2

Completed

Conditions: Obesity
Diabetes Mellitus
Prediabetic State

First Posted Date: 2003-07-03

Last Posted Date: 2010-01-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 240

Registration Number: NCT00063674

Locations: 🇺🇸
Stanford University School of Medicine, Palo Alto, California, United States

Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant

Phase 1

Completed

Conditions: Liver Disease
Lymphoproliferative Disorders

First Posted Date: 2003-07-03

Last Posted Date: 2010-01-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 50

Registration Number: NCT00063648

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Impact of Non-Commercialism Policy in Seattle Schools

Not Applicable

Completed

Conditions: Obesity

First Posted Date: 2003-07-03

Last Posted Date: 2010-01-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registration Number: NCT00063700

Locations: 🇺🇸
Seattle school, Seattle, Washington, United States

Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)

Phase 3

Completed

Conditions: Fatty Liver

Interventions: Drug: Matching placebo
Dietary Supplement: Vitamin E
Drug: Metformin

First Posted Date: 2003-07-03

Last Posted Date: 2012-09-27

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 173

Registration Number: NCT00063635

Locations: 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States

and more 7 locations

Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)

Phase 3

Completed

Conditions: Liver Diseases

Interventions: Drug: Matching placebo
Dietary Supplement: Vitamin E
Drug: Pioglitazone

First Posted Date: 2003-07-03

Last Posted Date: 2018-04-06

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 247

Registration Number: NCT00063622

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 5 locations

Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-06-26

Last Posted Date: 2015-04-28

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00040729

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy